International Session (Symposium)1 (JSH, JSGE, JSGS)

Stem cells in liver regeneration and therapy: Present and future scope

• Chairperson: G.Shiota
  (Department of Genetic Medicine and Regenerative Therapeutics, Tottori University)
• Chairperson: I.Sakaida
  (Department of Gastroenterology & Hepatology, Yamaguchi University Graduate School of Medicine)

IS-S1-1Matrix Metalloproteinase-14 controls differentiation of fetal hepatic stem/progenitor cells

IS-S1-2Lineage plasticity of cholangiocytes and hepatocytes in liver regeneration

IS-S1-3Attenuation of liver fibrosis development by angiotensin 2 receptor blocker 1- treatment augments hepatocyte differentiation of hepatic progenitor cells

IS-S1-4Stem cells in liver regeneration and therapy: present and future scope.

IS-S1-5The emerging role of hematopoietic stem cells in liver pathogenesis and regeneration

IS-S1-6New approaches to construction of liver tissue in vivo: Less invasive techniques and progenitor cells.

IS-S1-7Our regeneration therapies using autologous bone marrow cells for liver cirrhosis

IS-S1-8Transplantation of human amnion-derived mesenchymal stem cells ameliorates carbon tetrachloride-induced liver fibrosis in rats

IS-S1-9A Novel Therapy for Liver Fibrosis Using Ex Vivo Modified Mesenchymal Stem Cells

IS-S1-10Development of hepatic cell sheet therapy for liver injury

IS-S1-11Whole Organ Engineering for the clinical application of iPS cells

International Session (Symposium)2 (JSH, JSGE)

Mechanisms of hepatic and pancreatic fibrosis ; Clinical implications

• Chairperson: N.Kawada
  (Department of Hepatology, Osaka City University Medical School)
• Chairperson: H.Yoshiji
  (Department of Gastroenterology, Endocrinology and Metabolism, Nara Medical University)

IS-S2-KeynoteTHE RENIN-ANGIOTENSIN SYSTEM AS A TARGET TO TREAT LIVER FIBROSIS

IS-S2-1The impact of CTGF on liver fibrosis

IS-S2-2Cytoglobin deficiency enhances liver injury and fibrogenesis during cholestasis in mice

IS-S2-3RASAL1 prevents liver fibrosis by suppression TGF-β and PDGF signaling in hepatic stellate cells

IS-S2-4Maid is a specific guardian gene to regulate DNA damage in liver fibrosis and hepatocarcinogenesis

IS-S2-5Direct Contribution of Mitochondorial Oxidative Stress to Hepatic Fibrogenesis

IS-S2-6Mechanism of mediating macrophage- hepatic stellate cell crosstalk during liver fibrosis through chemokine receptor CCR9

IS-S2-7Spleen deficiency enhances liver fibrosis in mice

IS-S2-8Direct renin inhibitor attenuated the liver fibrosis development via suppression of angiotensin-II-mediated several biological activities

IS-S2-9Conophylline Suppresses Hepatic Stellate Cells and Attenuates Thioacetamide-induced Liver Fibrosis in Rats

IS-S2-10Pancreatic stellate cells activate Stat3 pathway in pancreatic cancer cells

IS-S2-11Pancreatic fat accumulation, fibrosis and acinar cell injury in the Type 2 diabetes model rat fed a chronic high-fat diet

IS-S2-12The impact of the four recently-found SNPs on liver fibrosis in chronic HBV and HCV hepatitis

IS-S2-13Fibrotic liver regeneration after hepatectomy. How far can we perform hepatectomy for HCC patients with fibrosis?

IS-S2-14Withdrawn

IS-S2-15A Promising Biomarker of Fibrogenesis in the Liver, TGF-beta LAP-D

International Session (Symposium)3 (JSGE)

Functional dyspepsia and its new perspective

• Chairperson: H.Miwa
  (Department of Gastroenterology, Hyogo College of Medicine)
• Chairperson: H.Suzuki
  (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine)

IS-S3-1Are GERD and FD cousin disease? The impact of GERD/EPS/PDS symptoms on patients' living status and QOL, and the efficacy of PPI treatment on each symptom.

IS-S3-2Comparison between endoscopic findings and dyspepsia symptoms in healthy subjects post-infected and uninfected with Helicobacter pylori: a case-control study

IS-S3-3Up regulations of gastric TRPV receptors and decreased serum concentration of BDNF in patients with Functional Dyspepsia

IS-S3-4Impaired gastric paracellular barrier in FD patients: in vivo evaluation by confocal endomicroscopy

IS-S3-5Epigenetic modification of serotonin transporter gene in the gastric mucosa of functional dyspepsia

IS-S3-6Childhood Abuse history is associated with the development of dyspepsia - a population-based survey

IS-S3-7Role of delayed gastric emptying in pathogenesis of PDS symptoms

IS-S3-8Effects of spicy foods and fatty foods on functional dyspepsia (FD) subtypes and the over-diagnosis of this condition in Thai patients.

IS-S3-9Efficacy of rabeprazole on functional dyspepsia in a multicenter clinical trial.

IS-S3-10Acotiamide increases food intake in hospitalized patients

International Session (Symposium)4 (JSGE)

Therapeutic strategy of IBS based on pathophysiology

• Chairperson: Y.Fujiyama
  (Shiga University of Medical Science)
• Chairperson: S.Fukudo
  (Department of Behavioral Medicine, Tohoku University Graduate School of Medicine)

IS-S4-1Peripheral corticotropin-releasing factor (CRF) induces stimulation of colonic contractions and visceral hyperalgesia in rats; role of CRF receptor type 1 and 2

IS-S4-2Vasoactive intestinal peptide (VIP) is involved in intraperitoneal corticotropin-releasing factor (CRF) induced diarrhea in rats

IS-S4-3Corticotropin-releasing hormone-induced changes in colonic tone in patients with irritable bowel syndrome

IS-S4-4Colonic mucosal N-methyl-D-aspartic receptor participates in pathogenesis of irritable bowel syndrome

International Session (Symposium)5 (JSGE, JGES, JSGS, JSGCS)

Prevention and early detection of colon cancer

• Chairperson: S.Fukuda
  (Department of Gastroenterology and Hematology, Hirosaki University)
• Chairperson: A.Nakajima
  (Department of Gastroenterology and Hepatology, Yokohama City University)

IS-S5-1Sphingosine kinase 1 mediates colon carcinogenesis

IS-S5-2Enhancing microRNA function may prevent colon carcinogenesis

IS-S5-3Suppressive effect of the farnesyltransferase inhibitor for aberrant crypt foci as a precursor of colorectal cancer

IS-S5-4Microbial dysbiosis is the cause of colorectal cancer onset

IS-S5-5Chemopreventive effect of eicosapentaenoic acid (EPA) for colorectal cancer

IS-S5-6Withdrawn

IS-S5-7A Comparison of Immunochemical Fecal Occult Blood Test and Total Colonoscopy in an Asymptomatic Population

IS-S5-8Measuring iron concentration in the gut lavage fluid is helpful for detecting colon cancer

IS-S5-9Randomized Comparison of Surveillance Intervals after Polypectomy: Results from the Japan Polyp Study

IS-S5-10Characteristics of Advanced Neoplasia Detected within 3 Years after Colonoscopy

IS-S5-11Consideration of adequate follow up period to avoid interval cancer

IS-S5-12The development of advanced adenoma after colorectal endoscopic submucosal dissection and appropriate follow-up colonoscopic examinations

IS-S5-13Metabolic factors and colorectal adenoma

IS-S5-14A "RESECT AND DISCARD" STRATEGY USING MAGNIFYING NARROW-BAND IMAGING: A PHASE II PROSPECTIVE STUDY

IS-S5-15Newly found polyps after removal of diminutive colorectal polyps: cold snare polypectomy vs. conventional polypectomy

IS-S5-16Potential utility of DNA methytlation as a biomarker for prediction of ulcerative colitis associated colorectal carcinoma (UCAC)

International Session (Symposium)6 (JGES, JSGE, JSGS)

EUS-guided therapy: Current status and future directions

• Chairperson: K.Yamao
  (Department of Gastroenterology, Aichi Cancer Center Hospital)
• Chairperson: R. H.Hawes
  (University of Central Florida College of Medicine, Florida Hospital Institute for Minimally Invasive Therapy)

IS-S6-1EUS in managing Pancreatic Fluid Collections

IS-S6-2EUS-guided transmural drainage of pancreatic fluid collections in 93 patients

IS-S6-3EUS-guided transpapillary biliary drainage

IS-S6-4EUS-guided rendezvous for difficult biliary cannulation: a multicenter prospective pilot study

IS-S6-5EUS-guided transmural Biliary Drainage (EUS-BD)

IS-S6-6Long-term outcomes and reinterventions in EUS-guided biliary drainage for malignant biliary obstruction

IS-S6-7EUS-guided gallbladder drainage

IS-S6-8Interventional EUS using a lumen-apposing designed metal stent in pancreaticobiliary diseases

IS-S6-9EUS-guided drainage of liver abscess drainage

IS-S6-10EUS-guided fine-needle injection/indwelling

IS-S6-11Predictive factors for pain relief after EUS-guided neurolysis in patients suffering from upper abdominal cancer pain

International Session (Symposium)7 (JGES, JSGE, JSGS)

Mucosal healing in IBD practice: Definition, prognostic significance and monitoring

• Chairperson: T.Matsui
  (Department of Gastroenterology, Fukuoka University Chikushi Hospital)
• Chairperson: Y.Suzuki
  (Department of Internal Medicine, Toho University Sakura Medical Center)

IS-S7-KeynoteMucosal healing in ulcerative colitis: what does it mean?

IS-S7-1Current status and issues on clinical indices of inflammatory bowel diseases

IS-S7-2Fecal calprotectin correlated better than C-Reactive Protein with the endoscopic index of severity for inflammatory bowel disease patients

IS-S7-3Evaluation of mucosal healing of ulcerative colitis with clinical remission by a fecal immunochemical test

IS-S7-4The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) is useful to evaluate endoscopic activity of ulcerative colitis patients treated with tacrolimus

IS-S7-5Withdrawn

IS-S7-6Correlation of Mucosal Healing with Surrogate Markers in Crohn's Disease

IS-S7-7Enteroscopic and MR findings of small intestine in Crohn's disease

IS-S7-8Usefulness of Evaluating Small-intestinal Mucosa in Mild Crohn's Disease (CD) Using Capsule Endoscopy (CE)

IS-S7-9Efficacy and safety of natalizumab for anti-TNF refractory Crohn's disease

IS-S7-10Diagnosis of Crohn's disease and other chronic enteropathies associated with prostaglandin deficiency

IS-S7-11Accurate prediction of IBD Prognosis using a colonoscopy: Is it real?